Why Haemonetics Stock Was on Fire Thursday
Niche healthcare stock (NYSE: HAE) was a winner among the clutch of publicly traded companies reporting quarterly earnings on Thursday. On the back of an estimates-beating second quarter of fiscal 2026, investors piled into its shares to push them in excess of 32% higher. That looked particularly impressive next to the bellwether S 500's (SNPINDEX: ^GSPC) 1.1% drop that trading session. On Friday, the rally continued, as the stock was up by over 3% that morning.
Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst expectation of under $312 million.
Image source: Getty Images.
Source Fool.com
Haemonetics Corp. Aktie
55,50 €
1,79 %
Reines Buy-Sentiment für Haemonetics Corp., keine Sell-Einschätzungen in Sicht.
Das Kursziel von 76 € für Haemonetics Corp. impliziert eine deutliche Steigerung um über 20% gegenüber 55.5 €.
